Unusually high risks of COVID-19 mortality with age-related comorbidities: An adjusted method to improve the risk assessment of mortality using the comorbid mortality data.

Andrew Antos, Ming Lai Kwong, Timothy Balmorez, Alyssa Villanueva, and Shin Murakami*.

Department of Basic Sciences, College of Osteopathic Medicine, Touro University, California, Vallejo, CA.

*** Corresponding author:** Shin Murakami, PhD, FGSA, Department of Basic Sciences, College of Osteopathic Medicine, Touro University California 1310 Club Drive, Mare Island, Vallejo, CA 94592. E-mail: shin.murakami@tu.edu

Author contributions: AA, MLK, TB and AV were involved in data analysis and manuscript preparation. SM has been involved in direction and all aspects of research.

Acknowledgment: We thank the members of the Murakami laboratory for useful discussion and technical assistance.

ABSTRACT

Background: The pandemic of Coronavirus Disease 2019 (COVID-19) has been a threat to global health in the world. In the US, the Centers for Disease Control and Prevention (CDC) has listed 12 comorbidities within the first tier that increase with the risk of severe illness from COVID-19, including the comorbidities that are common with increasing age (referred to as age-related comorbidities) and other comorbidities. However, the current method compares a population with and without a particular disease (or disorder), which may result in a bias on the results. Thus, comorbidity risks of COVID-19 mortality may be underestimated.

Objective: To re-evaluate the mortality data from US States and estimate the odds ratios of death by major comorbidities with COVID-19, we incorporated the control population with no comorbidity reported and assessed the risk of COVID-19 mortality with comorbidity.

Methods: We collected all the comorbidity data from the Public Health websites of fifty US States and Washington DC accessed on December 2020. The timing of the data collection should allow minimizing a bias from the COVID-19 vaccines and new COVID-19 variants. The comorbidity demographic data were extracted from the State Public Health data made available online. Using the inverse-variance random-effects model, we performed a comparative analysis and estimated the odds ratio of deaths by COVID-19 with pre-existing comorbidities.

Results: A total of 39,451 COVID-19 deaths were identified from four States that had comorbidity data, including Alabama, Louisiana, Mississippi, New York. 92.8% of the COVID-19 deaths were associated with pre-existing comorbidity. The risk of mortality associated with at least one comorbidity combined was 1,113 times higher than that with no comorbidity. The comparative analysis identified nine comorbidities with odds ratios of up to 35 times significantly higher than no comorbidities. Of them, the top four comorbidities were: hypertension (odds ratio 34.73; 95% CI 3.63-331.91; $p = 0.002$), diabetes (odds ratio 20.16; 95% CI 5.55-73.18; $p <$

0.00001), cardiovascular disease (odds ratio 18.91; 95% CI 2.88-124.38; p = 0.002); and chronic kidney disease (odds ratio 12.34; 95% CI 9.90-15.39; p < 0.00001). Interestingly, lung disease added only a modest increase in risk (odds ratio 6.69; 95% CI 1.06-42.26; p < 0.00001).

Conclusion: The aforementioned comorbidities show surprisingly high risks of COVID-19 mortality when compared to the population with no comorbidity. Major comorbidities were enriched with pre-existing comorbidities that are common with increasing age (cardiovascular disease, diabetes, and hypertension). The COVID-19 deaths were mostly associated with at least one comorbidity, which may be a source of the bias leading to the underestimation of the mortality risks previously reported. Taken together, this type of study is useful to approximate the risks, which most likely provide an updated awareness of age-related comorbidities.

INTRODUCTION

COVID-19 is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) [1]. It has infected over 82 million people worldwide and over 19 million people in the United States (John Hopkins University Corona Virus Online Map) [2] with cases increasing daily. As of 12/30/2020, over 1.8 million people have died from COVID-19 globally, and 341,313 deaths are currently attributed to COVID-19 in the US [2].

The Centers for Disease Control and Prevention (CDC) has published a list of medical conditions that increase the risk of severe illness from COVID-19 [3]. These comorbid diseases have two tiers; the first tier has 12 conditions that “are (an) increased risk of severe illness from the virus that causes COVID-19”; and the second tier has 11 conditions that “might be at an increased risk for severe illness from the virus that causes COVID-19” [4]. The CDC listed 125 publications for the evidence [4] (updated 11/30/2020; Accessed 3/28/2021). There are a few issues with the previous assessments. Firstly, the vast majority of them use data from other countries or mixtures of different countries. The US has a diverse population and COVID-19 has been disproportionately impacted compared to the rest of the world; therefore, the risk of COVID-19 should be adjusted based on the US population. Secondly, the current risk assessment of COVID-19 mortality compares a population with and without a particular disease (or disorder). If the vast majority of the COVID-19 deaths are expected to be with comorbidities, the control population without a particular disease would include the other comorbidities, resulting in a possibility of underestimation of the mortality risks. We reasoned that the control without pre-existing comorbidities should be appropriate as a control population for the mortality risk assessment. Here, we searched and identified provisional US-based data on the comorbidities, incorporated the control without pre-existing comorbidities, and successfully turned incomplete data into more reliable results.

METHODS

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement [5]. The US comorbidity data was searched on the PubMed, UpToDate, and Scopus websites. Fifty State health department and Washington DC websites were searched (Supplementary Material 1) and all the data were collected. Five states provided comorbidity data: Alabama, Louisiana, Mississippi, New York, and Pennsylvania. Pennsylvania was not included in our results because the state department reported incomplete data - noting that 38% of deaths did not include comorbidity data (Pennsylvania Department of Health) [6]. We found data from a study conducted in the State of Georgia, but this study did not list the deaths by comorbidity and thus was not included in this study.

The Alabama, Louisiana, Mississippi, and New York state department websites update the death tolls for their respective states. We referenced the Alabama [7], Mississippi [8], and New York data [9] which were updated on 12/29/2020. We retrieved Louisiana's data on 12/17/2020; the Louisiana data were dated on 3/31/2020 [10]. The data surrounding deaths due to COVID-19 in Alabama, Louisiana, Mississippi, and New York were separated and additionally summed for analysis. Deaths that included comorbidity were separated by their respective state. Deaths that did not suffer from comorbidity were also separated by state. To estimate the number of comorbidities in Louisiana, we multiplied the percentages with the total number of deaths since their data only provided a comorbidity percentage. We were unable to input the decimal values from the percentage calculations for Louisiana's numerical fields. Thus, we rounded up if the tenths decimal place was equal to or greater than five and rounded down if the tenths decimal place was less than five. For New York, we also subtracted the total deaths with comorbidity from the total deaths from COVID-19 to deduce how many COVID-19 deaths did not have comorbidity.

To calculate the odds ratios, we used the software, RevMan5 (Cochrane reviews) [11]. The random-effects method was also used to calculate the odds ratios. The inverse variance method was used since it is a common and simple mode to conduct a meta-analysis. “The inverse variance method is so named because the weight given to each study is chosen to be the inverse of the variance of the effect estimate (i.e. one over the square of its standard error). Thus, larger studies, which have smaller standard errors, are given more weight than smaller studies, which have larger standard errors. The inverse-variance random-effects model has been commonly used in the COVID-19 meta-analysis studies, for example, [12] and [13]. This choice minimizes the imprecision (uncertainty of the pooled effect estimate).” Statistical heterogeneity is measured as $I^2>0$. The following interpretations for different heterogeneity percentages were given:0% to 40% “might not be important”, 30% to 60% “may represent moderate heterogeneity”, 50% to 90% “may represent substantial heterogeneity”, and 75% to 100% “is considerable heterogeneity.” The “thresholds for the interpretation of I^2 can be misleading, since the importance of inconsistency depends on several factors.” These observed factors include the “magnitude and direction of effects” and “the strength of evidence for heterogeneity (e.g., P-value from the Chi-squared test, or a confidence interval for I^2).”

We organized the ten comorbidities between the states to standardize them for analysis as follows. Hypertension was documented in Mississippi and New York that were included to estimate odds ratios of hypertension. For cardiovascular disease (CVD), New York listed detailed diseases with CVD pathologies (atrial fibrillation, coronary artery disease, and stroke comorbidity) [9] and thus were included under the term CVD. Three states showed the data for the immunocompromised conditions, liver disease, and neurological disease odds ratios; and two states for the chronic kidney disease and obesity odds ratio figures. For chronic kidney diseases (CKD) and renal disease (RD), CKD is a part of Renal Disease (RD), and thus RD data include CKD; nonetheless, we did perform the analysis of CKD. The WHO designates

stroke as a neurological disorder [14] and the CDC designates it as cardiovascular or cerebrovascular disease [3]. We followed the CDC designation and thus included stroke data into the cardiovascular disease odds ratios. New York had more detailed designations than other States and we treated the New York data as follows. Dementia data were included into Neurologic Disease, and COPD was included in Lung Disease. In this study, Neurological disease was called Neurologic disease for the consistency of disease designations. Despite the designations by the CDC, the four states also did not distinguish the diabetes types (type 1, type 2, other types of diabetes) and is shown as diabetes.

RESULTS

We modified the assessment procedure of the COVID-19 mortality data and used the control population with no comorbidity (Methods). We focused on mortality data, since the outcomes from the COVID-19 test results could be influenced by different testing systems and by how they were administered and recorded. For the reason, we excluded the COVID-19 test results. Similarly, we excluded hospitalization that may contribute to a bias of the risk assessment. The US comorbidity data was searched on the PubMed, UpToDate, and Scopus websites. The results from queries were reviewed and data regarding deaths from patients with and without comorbidity were not found. Thus, the CDC and State websites were searched for provisional comorbidity data. The CDC had a provisional dataset of “comorbidities and other conditions”; the dataset was dominated by “pneumonia and influenza”, “respiratory failure” and “hypertensive diseases” [15] which were mixed with COVID-19 symptoms, causes of deaths and pre-existing conditions. Thus, we did not use the CDC dataset.

We collected all the data available as of December 2020 by searching the Public Health websites of fifty States and Washington DC in the US. We have compiled and organized the ten comorbidities between the states to standardize them for analysis (Table 1). The demography is summarized in Supplementary Material 2. More details are described in the Section of Method.

150 A total of 39,451 COVID-19 deaths were found from four states including Alabama, Louisiana,
151 Mississippi, and New York. The results of the total deaths and other separations by the state are
152 summarized in Figure 1. Each of the pre-existing comorbidities associated with COVID-19 is
153 summarized in Figure 2. New York accounts for most of the total COVID-19 deaths in this
154 study, which may create a bias by dominating the result. To minimize the bias, we used the
155 random-effects models to control the results of the odds ratio. As a comparison, New York
156 accounted for 75.4% of the total deaths in the study while Mississippi accounted for 11.9%.
157 Alabama accounted for 12%, while Louisiana accounted for 0.6% of the total deaths in the
158 study. Therefore, the random-effects model helped mitigate some of the bias from New York.
159 92.8% of the COVID-19 mortality was seen in patients with at least one comorbidity.

160 Table 1 and Figure 2 summarize the results. Nine out of ten comorbidities combined to
161 show a surprisingly high risk of death due to covid-19, 1,113 times higher (odds ratio, 1113.59;
162 95% CI, 157.59, 7888.28; p <.00001). Of all the comorbidities, the top comorbidities were:
163 cardiovascular disease; chronic kidney disease, diabetes; and hypertension. Nine comorbidities,
164 except chronic kidney disease, showed a significant amount of heterogeneity (I^2 value ranging
165 from 77% to 100%) present which was supported by a strong heterogeneity p-value (ranging
166 from 0.00001 to 0.01) and high variability in the confidence interval (Table 1).

167 As shown in Figure 3A, cardiovascular disease has a high risk of death due to covid-19
168 (odds ratio 18.91; 95% CI 2.88-124.38; p = 0.002). Hypertension is often coupled with
169 cardiovascular disease, and when we combined both hypertension and cardiovascular disease,
170 the risk was doubled (odds ratio, 40.70; 95% CI 27.06, 61.21; p < 0.00001). Figure 3B shows
171 the chronic kidney disease (CKD) comorbidity data (odds ratio 12.34; 95% CI 9.90-15.39; p <
172 0.00001). Importantly, no heterogeneity (I^2 = 0%) was present in CKD which is supported by the
173 weak P-value (P = 0.58) and significant overlap of confidence intervals between the two
174 studies. Figure 3C shows the diabetes comorbidity data (odds ratio 20.16; 95% CI 5.55-73.18; p

175 < 0.00001). Figure 3D shows the hypertension analysis containing comorbidity data (odds ratio
176 34.73; 95% CI 3.63-331.91; p = 0.002). A significant amount of heterogeneity (I^2 = 99%) was
177 present in this analysis which was supported by a strong P-value (P< 0.00001) and no
178 significant overlap of the confidence intervals between the two studies.

179 Figure 3E shows the immunocompromised condition comorbidity data (odds ratio, 6.89;
180 95% CI 3.89, 12.20; p < 0.00001); Figure 3F shows the liver disease comorbidity data (odds
181 ratio, 2.04;95% CI 3.89, 12.20; p = 0.02); and Figure 3G shows the lung disease comorbidity
182 data (odds ratio, 6.69; 95% CI 1.06, 42.26; p = 0.04). The effect of lung disease as a type of
183 comorbidity may have an overlapping, modest effect of death. Neurological condition (Figure
184 3H) was not significantly different from no comorbidity (odds ratio, 5.41; 95% CI 0.55, 38.63; p =
185 0.07). It is worth noting that in New York, dementia is one of the leading comorbidities of the
186 COVID-19 deaths, which will require a more specific detailed analysis. Obesity (Figure 3I) had
187 an estimate of 9 (95% CI 1.59, 51.06; p = 0.01). The renal disease (Figure 3J) had an estimate
188 of 7.74 (p = 0.02).

189 **DISCUSSION**

190 Age-related health conditions including cardiovascular disease, hypertension, and type 2
191 diabetes are common in the aging population and have been implicated in late-life diseases
192 such as Alzheimer's disease [16-17]. The centers for disease control and prevention (CDC)
193 have listed comorbidities with the risk of severe illness from COVID-19, including the
194 comorbidities that are common with increasing age (age-related comorbidities) (e.g., heart
195 conditions, hypertension, and type 2 diabetes) and other comorbidities (e.g., smoking, lung
196 disease, and genetic conditions such as down syndrome and sickle cell disease). Most of the
197 previous studies on comorbidities were based on data from other countries. Using the data
198 available from the US, we estimated the odds ratios of comorbidities within the US population to
199 assess their impact on mortality from COVID-19. We found age-related comorbidities to be the

major conditions: cardiovascular disease, chronic kidney disease, diabetes, and hypertension. When cardiovascular disease and hypertension were combined, the odds ratio of mortality became 40 times higher than without comorbidity. The risks of mortality from COVID-19 in patients with medical comorbidities appears to be much higher than previous studies that used non-US data. For example, the CDC refers to the studies about hypertension consist most if not all of non-US data (cdc.gov accessed on March 2021). The odds ratios were much higher in the US (odds ratio 34.7; this study) compared to those in studies conducted in non-US-countries (odds ratios 2.3-6.5 in non-US countries) [e.g., 17-20], which implies that there seems to be a variation among countries. Thus, a more comprehensive study remains to be done with data from more US states once they become available.

We organized the comorbidity categories with consideration given to the varied definitions of categories between organizations and state reports. In the study, we followed the CDC categories whenever possible. Adjustments of the categories for the purposes of analysis in this study are described in the Result and Method sections. We also noted that the CDC has a detailed list of diseases contributing to the cause of death, which is dominated by “pneumonia and influenza” and “respiratory failure” in the category [15]. In our analysis, we used pre-existing comorbidities present in the population of the study. We tried to avoid skewed results by using the inverse variance method of data analysis to ensure that the data from New York did not overpower data from the other states. Despite the adjustments, the odds ratios were surprisingly higher than those estimated based on previous research

Most of the comorbidities showed significantly higher mortality as measured by the odds ratio. Comorbidities that significantly increase the risk of a severe COVID-19 include cardiovascular disease, chronic kidney disease, diabetes, hypertension, immunocompromised condition, liver disease, lung disease, obesity, and renal disease. We could not find a significant increase in risk due to neurological conditions. Heterogeneity was significantly high for nine

225 comorbidities, except for chronic kidney disease. Interestingly, dementia, a part of the
226 neurological conditions, was placed in fourth for comorbidities in New York, while other states
227 did not have this category. Therefore, it remains contested whether or not dementia shows a
228 significant increase in mortality with COVID-19.

229 We used an adjusted method that has strengths as follows. Firstly, it uses the control
230 population with no comorbidities which avoid bias from the population. The control is particularly
231 important when most of the COVID-19 deaths are associated with one or more comorbidities.
232 Secondly, the mortality data with comorbidities are readily available to the public, which are
233 expected to be less biased. The sample sizes are similar to the previous systematic review and
234 meta-analysis studies [4,18-21]. Thirdly, it is relatively simple to perform the assessment
235 independent of other factors that are expected to have high variability. Finally, we designed the
236 method that avoids the sources of data ambiguity, such as COVID-19 detection systems and
237 variation of the severity of COVID-19. In contrast, the method has limitations stemming primarily
238 from the availability of the data. It is limited to the resources that have comorbidity data made
239 available to the public, though the limitation is similar to that of the meta-analysis. We were also
240 not able to identify the data about more than one comorbidity, which cannot be assessed in the
241 method. Other limitations have been described above (Methods; Results). We also note that the
242 comorbidity criteria are inconsistently presented among the States. We propose to have a more
243 unified process of presenting the comorbidities in Public Health data for collaboration purposes.

244 CONCLUSIONS

245 This study is among one of the first US-based studies to show the risk of mortality from
246 COVID-19 in patients who suffer from common comorbidities. We successfully compiled the US
247 COVID-19 mortality data and estimated the risk of death from COVID-19 with and without
248 comorbidity. This type of study is needed to approximate mortality risk in the context of COVID-
249 19 so that we can better stratify how to address and manage patients with these comorbidities

250 from a public health perspective. Nine out of ten comorbidities analyzed were shown to increase
251 the likelihood of death from COVID-19. We found that in the US population, the odds ratio for
252 each of these comorbid conditions was higher than that previously seen in the studies
253 predominantly from outside of the US. We call for a standardized format and distribution of data
254 be provided by each State regarding COVID-19 morbidity and mortality so that a thorough and
255 cohesive analysis of data can occur. We also propose to include a control population with no
256 comorbidity when possible to minimize a bias from other health conditions. Altogether, this study
257 gives an awareness about the comorbidities that are more deleterious than previously
258 recognized and provides a call to action for the public health community.

REFERENCES

1. Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *The Lancet Respiratory Medicine*, *8*(4). doi: 10.1016/s2213-2600(20)30116-8 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30116-8/fulltext
2. Dong E, Du H, Gardner L. (2020) An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30120-1/fulltext
3. The centers for disease control and prevention (CDC). People with Certain Medical Conditions. COVID-19. Retrieved 18 Aug. 2020 from https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
4. The centers for disease control and prevention (CDC). Underlying Medical Conditions Associated with High Risk for Severe COVID-19: Information for Healthcare Providers Retrieved December 29, 2020 from https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html
5. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. (2015) Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 4(1):1. doi: 10.1186/2046-4053-4-1 https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/2046-4053-4-1
6. Pennsylvania Department of Health. Weekly Report For Deaths Attributed To COVID-19. Retrieved May 17, 2020 from https://www.health.pa.gov/topics/Documents/Diseases%20and%20Conditions/COVID-19%20Death%20Reports/Weekly%20Report%20of%20Deaths%20Attributed%20to%20COVID-19%20--%202020-05-17.pdf?mod=article_inline

7. Alabama Public Health. Data and Surveillance. Retrieved December 29, 2020 rom https://www.alabamapublichealth.gov/covid19/data.html
8. Mississippi State Department of Health. Interactive Charts: COVID-19 Epidemiological Charts and Trends. Retrieved December 29, 2020 from https://msdh.ms.gov/msdhsite/_static/14,21995,420,873.html
9. New York State Department of Health. Workbook: NYS-COVID19-Tracker. (n.d.). Retrieved December 30, 2020 from https://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/NYSDOHCOVID-19Tracker-Fatalities?%3Aembed=yes&%3Atoolbar=no&%3Atabs=n
10. Louisiana Department of Health. Updates for 3/31/2020. (n.d.). Retrieved December 17, 2020 from https://ldh.la.gov/index.cfm/newsroom/detail/5522
11. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). (2019) Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons. Cochrane, 2019. www.training.cochrane.org/handbook.
12. Miller LE, Bhattacharyya R, Miller AL. (2020) Diabetes mellitus increases the risk of hospital mortality in patients with Covid-19: Systematic review with meta-analysis. Medicine (Baltimore). 2020 Oct 2;99(40):e22439. doi: 10.1097/MD.0000000000022439. PMID: 33019426 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535849/
13. Li J, Yue J, Zhang S, Wu J, Lian R, Zhang R, Cheng P. Medicine (Baltimore). (2020) Relationship between digestive diseases and COVID-19 severity and mortality: A protocol for systematic review and meta-analysis. 99(48):e23353. doi: 10.1097/MD.0000000000023353. PMID: 33235103 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710250/

308 14. World Health Organization (WHO). (2016) What are neurological disorders and how
309 many people are affected by them? (n.d.). Retrieved from https://www.who.int/news-
310 room/q-a-detail/what-are-neurological-disorders
311 15. The centers for disease control and prevention (CDC). Weekly Updates by Select
312 Demographic and Geographic Characteristics. Retrieved March 31, 2021 from
313 https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm
314 16. Vahdati Nia B, Kang C, Tran MG, Lee D, Murakami S. (2017) Meta Analysis of Human
315 AlzGene Database: Benefits and Limitations of Using C. elegans for the Study of
316 Alzheimer's Disease and Co-morbid Conditions. Front Genet. 12;8:55. doi:
317 10.3389/fgene.2017.00055. https://doi.org/10.3389/fgene.2017.00055
318 17. Le D, Crouch N, Villanueva A, Ta P, Dmitriyev R, et al. 2020. Evidence-Based Genetics
319 and Identification of Key Human Alzheimer's Disease Alleles with Co-morbidities. J
320 Neurol Exp Neurosci 6(1): 20-24. https://touroscholar.touro.edu/tuccom_pubs/139/
321 18. Matsushita K, Ding N, Kou M, Hu X, Chen M, Gao Y, Honda Y, Zhao D, Dowdy D, Mok
322 Y, Ishigami J, Appel LJ. 2020 The Relationship of COVID-19 Severity with
323 Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and
324 Meta-Analysis. Glob Heart, 15(1):64. doi: 10.5334/gh.814
325 https://globalheartjournal.com/article/10.5334/gh.814/
326 19. Guo, X., Y. Zhu, and Y. Hong. 2020 Decreased Mortality of COVID-19 With Renin-
327 Angiotensin-Aldosterone System Inhibitors Therapy in Patients with Hypertension: A
328 Meta-Analysis. Hypertension, 76(2):e13-e14. doi:
329 10.1161/HYPERTENSIONAHA.120.15572
330 https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.15572
331 20. Wu T, Zuo Z, Kang S, Jiang L, Luo X, Xia Z, Liu J, Xiao X, Ye M, Deng M. 2020 Multi-
332 organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis.

333 Aging Dis, 11(4): 874-894. doi: 10.14336/AD.2020.0520
334 http://www.aginganddisease.org/EN/10.14336/AD.2020.0520
335 **21.** Zhang J, Wu J, Sun X, Xue H, Shao J, Cai W, Jing Y, Yue M, Dong C. 2020 Association
336 of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis.
337 Epidemiol Infect 148:e106. doi: 10.1017/S095026882000117X
338 https://www.cambridge.org/core/journals/epidemiology-and-infection/article/association-
339 of-hypertension-with-the-severity-and-fatality-of-sarscov2-infection-a-
340 metaanalysis/4116FAD7D866737099F976E7E7FAEB15

341 **TABLE**

342 **Table 1. Summary of the odds ratio outcomes.**

Comorbidity Type	OR (95% CI)	P	I^2	Heterogeneity P
Cardiovascular Disease	18.91 (2.88, 124.38)	0.002	100%	< 0.00001
Chronic Kidney Disease	12.34 (9.90, 15.39)	< 0.00001	0%	0.58
Diabetes	20.16 (5.55, 73.18)	< 0.00001	99%	< 0.00001
Hypertension	34.73 (3.63, 331.91)	0.002	99%	< 0.00001
Immunocompromised	6.89 (3.89, 12.20)	< 0.00001	81%	0.006
Liver Disease	2.04 (3.89, 12.20)	0.02	77%	0.01
Lung Disease	6.69 (1.06, 42.26)	0.04	100%	< 0.00001
Neurological Disease	4.62 (0.55, 38.63)	0.16	99%	< 0.00001
Obesity	9.00 (1.59, 51.06)	0.01	98%	< 0.00001
Renal Disease	7.74 (1.33, 45.05)	0.02	100%	< 0.00001
All comorbidities combined	1113.59 (157.59, 7888.28)	< 0.00001	100%	< 0.00001

343 Abbreviation: OR (Odds Ratio)

344 **FIGURE LEGENDS**

345 **Figure 1.** A total number of COVID-19 deaths first separated by state and then by
346 comorbidity. A list of COVID-19 deaths was identified from a total of 4 US states in
347 2020, including Alabama, Louisiana, Mississippi, and New York.

348 **Figure 2**. Summary of the mortality risks by COVID-19 comorbidities.

349 **Figure 3.** Meta-analysis of the comorbidities with COVID-19. **A.** Cardiovascular disease (CVD).
350 This odds ratio includes atrial fibrillation, coronary artery disease, hypertension, and stroke from
351 New York's comorbidity data. **B.** Chronic Kidney Disease (CKD). **C.** Diabetes. **D.** Hypertension.
352 **E.** Immunocompromised Condition. **F.** Liver Disease. **G.** Lung Disease. This odds ratio includes
353 Chronic Lung Disease from Alabama's data and COPD from New York's data. **H.** Neurological
354 Disease. This odds ratio includes Alzheimer's disease and Stroke data from New York. **I.**
355 Obesity. **J.** Renal Disease. This odds ratio includes CKD data from Alabama and Louisiana.
356 "Total" columns in the model represent the numerical amount of the total deaths from COVID-
357 19. The "Events" column on the left represents the number of deaths that included the
358 cardiovascular disease comorbidity in that respective state. The "Events" column on the right
359 represents the number of deaths without comorbidity in that respective state.


COVID-19 Deaths from four states: 39,451
Alabama: 4,737 deaths
Louisiana: 239 deaths
Mississippi: 4,719 deaths
New York: 29,756 deaths
With cardiovascular disease: 2,368
With diabetes: 1,559
With chronic renal disease: 867
With chronic lung disease: 936
With Immunocompromised condition: 620
With obesity: 203
With chronic liver disease: 159
No comorbidity: 83
With diabetes: 96
With obesity: 60
With chronic kidney disease: 55
With cardiovascular disease: 50
With pulmonary disease: 29
With neurological disease: 14
With immunocompromised condition: 10
With chronic liver disease: 5
No comorbidity: 7
With hypertension: 1,878
With cardiovascular disease: 1,388
With diabetes: 1,149
With obesity: 649
With neurologic conditions: 681
With lung disease: 679
With renal disease: 616
With immunocompromised condition: 283
With liver disease: 94
No comorbidity: 28
With hypertension: 15,712
With diabetes: 10,215
With hyperlipidemia: 6,190
With dementia: 4,227
With coronary artery disease: 3,638
With renal disease: 3,163
With COPD: 3,034
With atrial fibrillation: 2,496
With cancer: 2,405
With stroke: 1,904
No comorbidity: 2,732

Figure 1


Odds of Death from COVID-19
40
35
30
25
20
15
10
5
0
18.91
12.34
20.16
34.73
6.89
2.04
6.69
4.62
9
7.74
Cardiovascular Disease
Chronic Kidney Disease
Diabetes
Hypertension
Immunocompromised Conditions
Liver Disease
Lung Disease
Neurological Disease
Obesity
Renal Disease
Comorbidity Type

Figure 2

A

Study or Subgroup	Pts w/ CVD Events	Pts w/ CVD Total	Pts w/o Comorbidity Events	Pts w/o Comorbidity Total	Weight	Odds Ratio IV, Random, 95% CI
Alabama State Health Department 2020	2368	4737	83	4737	25.3%	56.05 [44.78, 70.15]
Louisiana State Health Department 2020	50	239	7	239	24.2%	8.77 [3.89, 19.79]
Mississippi State Health Department 2020	1388	4719	28	4719	25.1%	69.81 [47.90, 101.75]
New York State Health Department 2020	8038	29756	2732	29756	25.4%	3.66 [3.49, 3.84]
Total (95% CI)		**39451**		**39451**	**100.0%**	**18.91 [2.88, 124.38]**
Total events	11844		2850			

Heterogeneity: $Tau^2 = 3.64$; $Chi^2 = 761.28$, df = 3 ($P < 0.00001$); $I^2 = 100\%$
Test for overall effect: Z = 3.06 (P = 0.002)



B

Study or Subgroup	Pts w/ CKD Events	Pts w/ CKD Total	Pts w/o Comorbidity Events	Pts w/o Comorbidity Total	Weight	Odds Ratio IV, Random, 95% CI
Alabama State Health Department 2020	867	4737	83	4737	92.6%	12.56 [9.99, 15.80]
Louisiana State Health Department 2020	55	239	7	239	7.4%	9.91 [4.41, 22.27]
Total (95% CI)		**4976**		**4976**	**100.0%**	**12.34 [9.90, 15.39]**
Total events	922		90			

Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 0.31$, df = 1 ($P = 0.58$); $I^2 = 0\%$
Test for overall effect: Z = 22.33 ($P < 0.00001$)



C

Study or Subgroup	Pts w/ Diabetes Events	Pts w/ Diabetes Total	Pts w/o Comorbidity Events	Pts w/o Comorbidity Total	Weight	Odds Ratio IV, Random, 95% CI
Alabama State Health Department 2020	1559	4737	83	4737	25.6%	27.51 [21.96, 34.46]
Louisiana State Health Department 2020	96	239	7	239	23.5%	22.25 [10.05, 49.28]
Mississippi State Health Department 2020	1149	4719	28	4719	25.2%	53.92 [36.97, 78.64]
New York State Health Department 2020	10215	29756	2732	29756	25.8%	5.17 [4.94, 5.41]
Total (95% CI)		**39451**		**39451**	**100.0%**	**20.16 [5.55, 73.18]**
Total events	13019		2850			

Heterogeneity: $Tau^2 = 1.68$; $Chi^2 = 351.98$, df = 3 ($P < 0.00001$); $I^2 = 99\%$
Test for overall effect: Z = 4.57 ($P < 0.00001$)



D

Study or Subgroup	Pts w/ HTN Events	Pts w/ HTN Total	Pts w/o Comorbidity Events	Pts w/o Comorbidity Total	Weight	Odds Ratio IV, Random, 95% CI
Mississippi State Health Department 2020	1878	4719	28	4719	49.7%	110.75 [76.04, 161.30]
New York State Health Department 2020	15712	29756	2732	29756	50.3%	11.07 [10.57, 11.58]
Total (95% CI)		**34475**		**34475**	**100.0%**	**34.73 [3.63, 331.91]**
Total events	17590		2760			

Heterogeneity: $Tau^2 = 2.63$; $Chi^2 = 142.04$, df = 1 ($P < 0.00001$); $I^2 = 99\%$
Test for overall effect: Z = 3.08 (P = 0.002)



E

Study or Subgroup	Pts w/ Immunocompromised Events	Pts w/ Immunocompromised Total	Pts w/o Comorbidity Events	Pts w/o Comorbidity Total	Weight	Odds Ratio IV, Random, 95% CI
Alabama State Health Department 2020	620	4737	83	4737	42.0%	8.44 [6.69, 10.66]
Louisiana State Health Department 2020	14	239	7	239	20.7%	2.06 [0.82, 5.20]
Mississippi State Health Department 2020	283	4719	28	4719	37.3%	10.69 [7.23, 15.79]
Total (95% CI)		**9695**		**9695**	**100.0%**	**6.89 [3.89, 12.20]**
Total events	917		118			

Heterogeneity: $Tau^2 = 0.19$; $Chi^2 = 10.31$, df = 2 ($P = 0.006$); $I^2 = 81\%$
Test for overall effect: Z = 6.61 ($P < 0.00001$)



F

Study or Subgroup	Pts w/ Liver Disease Events	Pts w/ Liver Disease Total	Pts w/o Comorbidity Events	Pts w/o Comorbidity Total	Weight	Odds Ratio IV, Random, 95% CI
Alabama State Health Department 2020	159	4737	83	4737	44.2%	1.95 [1.49, 2.55]
Louisiana State Health Department 2020	5	239	7	239	16.9%	0.71 [0.22, 2.26]
Mississippi State Health Department 2020	94	4719	28	4719	38.9%	3.41 [2.23, 5.20]
Total (95% CI)		**9695**		**9695**	**100.0%**	**2.04 [1.13, 3.68]**
Total events	258		118			

Heterogeneity: $Tau^2 = 0.19$; $Chi^2 = 8.52$, df = 2 ($P = 0.01$); $I^2 = 77\%$
Test for overall effect: Z = 2.36 (P = 0.02)



G

Study or Subgroup	Pts w/ Lung Disease Events	Pts w/ Lung Disease Total	Pts w/o Comorbidity Events	Pts w/o Comorbidity Total	Weight	Odds Ratio IV, Random, 95% CI
Alabama State Health Department 2020	936	4737	83	4737	25.3%	13.81 [10.99, 17.35]
Louisiana State Health Department 2020	29	239	7	239	24.1%	4.58 [1.96, 10.67]
Mississippi State Health Department 2020	679	4719	28	4719	25.1%	28.16 [19.25, 41.19]
New York State Health Department 2020	3034	29756	2732	29756	25.4%	1.12 [1.06, 1.19]
Total (95% CI)		**39451**		**39451**	**100.0%**	**6.69 [1.06, 42.26]**
Total events	4678		2850			

Heterogeneity: $Tau^2 = 3.48$; $Chi^2 = 694.49$, df = 3 ($P < 0.00001$); $I^2 = 100\%$
Test for overall effect: Z = 2.02 (P = 0.04)



Figure 3

H

Study or Subgroup	Pts w/ Neuro Disorder Events	Total	Pts w/o Comorbidity Events	Total	Weight	Odds Ratio IV, Random, 95% CI
Louisiana State Health Department 2020	14	239	7	239	32.1%	2.06 [0.82, 5.20]
Mississippi State Health Department 2020	681	4719	28	4719	33.8%	28.25 [19.32, 41.33]
New York State Health Department 2020	4227	29756	2732	29756	34.1%	1.64 [1.56, 1.72]
Total (95% CI)		**34714**		**34714**	**100.0%**	**4.62 [0.55, 38.63]**
Total events	4922		2767			

Heterogeneity: $Tau^2 = 3.44$; $Chi^2 = 211.78$, df = 2 ($P < 0.00001$); $I^2 = 99\%$
Test for overall effect: Z = 1.41 (P = 0.16)



I

Study or Subgroup	Pts w/ Obesity Events	Total	Pts w/o Comorbidity Events	Total	Weight	Odds Ratio IV, Random, 95% CI
Alabama State Health Department 2020	203	4737	83	4737	34.1%	2.51 [1.94, 3.25]
Louisiana State Health Department 2020	60	239	7	239	32.0%	11.11 [4.96, 24.89]
Mississippi State Health Department 2020	649	4719	28	4719	33.8%	26.72 [18.26, 39.09]
Total (95% CI)		**9695**		**9695**	**100.0%**	**9.00 [1.59, 51.06]**
Total events	912		118			

Heterogeneity: $Tau^2 = 2.28$; $Chi^2 = 104.47$, df = 2 ($P < 0.00001$); $I^2 = 98\%$
Test for overall effect: Z = 2.48 (P = 0.01)



J

Study or Subgroup	Pts w/ Renal Disease Events	Total	Pts w/o Comorbidity Events	Total	Weight	Odds Ratio IV, Random, 95% CI
Alabama State Health Department 2020	867	4737	83	4737	25.3%	12.56 [9.99, 15.80]
Louisiana State Health Department 2020	55	239	7	239	24.1%	9.91 [4.41, 22.27]
Mississippi State Health Department 2020	616	4719	28	4719	25.1%	25.15 [17.18, 36.82]
New York State Health Department 2020	3163	29756	2732	29756	25.4%	1.18 [1.11, 1.24]
Total (95% CI)		**39451**		**39451**	**100.0%**	**7.74 [1.33, 45.05]**
Total events	4701		2850			

Heterogeneity: $Tau^2 = 3.18$; $Chi^2 = 634.97$, df = 3 ($P < 0.00001$); $I^2 = 100\%$
Test for overall effect: Z = 2.28 (P = 0.02)



Figure 3 cont.

Supplementary Material 1

The list of the Public Health weblinks of fifty State and the Washington, D.C. websites searched in this study (as of Dec 2020)

1. Alabama: https://www.alabamapublichealth.gov/index.html
2. Alaska: http://hss.state.ak.us/outage.htm
3. Arizona: https://www.azdhs.gov/
4. Arkansas: https://healthy.arkansas.gov/
5. California: https://www.cdph.ca.gov/
6. Colorado: https://cdphe.colorado.gov/
7. Connecticut: https://portal.ct.gov/dph
8. Delaware: https://www.dhss.delaware.gov/dhss/dph/index.html
9. Washington DC: https://dchealth.dc.gov/
10. Florida; http://www.floridahealth.gov/
11. Georgia: https://dph.georgia.gov/
12. Hawaii: https://health.hawaii.gov/
13. Idaho: https://healthandwelfare.idaho.gov/
14. Illinois: https://www.dph.illinois.gov/
15. Indiana: https://www.in.gov/isdh/
16. Iowa: https://idph.iowa.gov/
17. Kansas: https://www.kdheks.gov/
18. Kentucky: https://chfs.ky.gov/agencies/dph/Pages/default.aspx
19. Louisiana: https://ldh.la.gov/
20. Maine: https://www.maine.gov/dhhs/
21. Maryland: https://health.maryland.gov/pages/home.aspx
22. Massachusetts: https://www.mass.gov/orgs/department-of-public-health
23. Michigan: https://www.michigan.gov/mdhhs
24. Minnesota: https://www.health.state.mn.us/
25. Mississippi: https://msdh.ms.gov/
26. Missouri: https://health.mo.gov/index.php
27. Montana: https://dphhs.mt.gov/
28. Nebraska: dhhs.ne.gov/Pages/default.aspx

29. Nevada: http://dpbh.nv.gov/
30. New Hampshire: https://www.dhhs.nh.gov/
31. New Jersey: https://www.nj.gov/health/
32. New Mexico: https://www.nmhealth.org/
33. New York: https://health.ny.gov/
34. North Carolina: https://www.ncdhhs.gov/
35. North Dakota: https://www.health.nd.gov/
36. Ohio: https://odh.ohio.gov/wps/portal/gov/odh/home
37. Oklahoma: https://oklahoma.gov/health.html
38. Oregon: https://www.oregon.gov/oha/ph/pages/index.aspx
39. Pennsylvania: https://www.health.pa.gov/Pages/default.aspx
40. Rhode Island: https://health.ri.gov/
41. South Carolina: https://scdhec.gov/
42. South Dakota: https://doh.sd.gov/
43. Tennessee: https://www.tn.gov/health.html
44. Texas: https://dshs.state.tx.us/
45. Utah: https://health.utah.gov/
46. Vermont: https://www.healthvermont.gov/
47. Virginia: https://www.vdh.virginia.gov/
48. Washington: https://www.doh.wa.gov/
49. West Virginia: https://dhhr.wv.gov/bph/Pages/default.aspx
50. Wisconsin: https://www.dhs.wisconsin.gov/
51. Wyoming: https://health.wyo.gov/

Supplementary Material 2

Demography of the population used in this study.

State Health Department	# of Deaths	Gender			Race							Access Date
		Male	Female	Unknown	White	Black	Asian	American Indian or Alaska Native	Unknown	Other	Hispanic	
Alabama	4,737*	2,487 (53%)	2,240 (47%)	10 (0.2%)	2,723 (58%)	1,544 (33%)	18 (0.4%)	NA	307 (7%)	146 (3%)	**	12/29/20
Louisiana	239	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	12/17/20
Mississippi	4,719	NA	NA	NA	2,441	1,964	15	94	125	80	**	12/29/20
New York	29,756	16,849 (57%)	12,898 (43%)	9 (0.0%)	NYC 27% NYS Excluding NYC 66% ***	NYC 28% NYS Excluding NYC 15% ***	NYC 7% NYS Excluding NYC 4% ***	NA	NA	NYC 4% NYS Excluding NYC 3% ***	NYC 34% NYS Excluding NYC 12% ***	12/29/20

Abbreviations: NA (Not available), NYC (New York City), NYS (New York State).

* The Alabama percentages by race add up more than 100%. It is a possibility of patients in two or more race.

** Alabama and Mississippi label Hispanic as an ethnicity, but not a race. Alabama reports 109 of the total deaths were of Hispanic ethnicity and Mississippi reports 50 deaths were of Hispanic ethnicity.

*** NYC data and NYS excluding NYC data were available as percentages shown. The numbers were not available.